Genmab — December 2024

[Darvin]

Og Børsen: https://borsen.dk/nyheder/virksomheder/genmab-leverer-igen-lovende-data-fra-kraefthab?b_source=borsen&b_medium=row_0&b_campaign=list_3

[Dusør]

Det ligner højt humør i morgen på Børsen. Vi kan håbe det kunne være den besked der vende trenden. Til det posiktive.

[nohope]

US tager det ret roligt.

[deleted-user]

Tak for den skarpe analyse nohope

[PederT]

Thomas Bowers fra Danske skifter til SEB. Ham har jeg nu alle dage synes godt om. Forhåbentlig fortsætter han sit syn på Genmab i den nye rolle. https://www.linkedin.com/posts/thomas-bowers-36394b4_jeg-er-glad-for-at-kunne-dele-at-jeg-starter-activity-7268918631357431808-ppx2?utm_source=share&utm_medium=member_android

[Solsen]

https://www.linkedin.com/posts/janvandewinkel_throughout-2024-ive-had-great-opportunities-activity-7271998920598204418-okxc?utm_source=share&utm_medium=member_ios JW tanker…

[bibob]

God morgen.

[E_L]

AbbVie, Genmab tout Epkinly combos in earlier lines of non-Hodgkin lymphoma https://endpts.com/ash24-abbvie-genmab-tout-epkinly-combination-in-earlier-lines-of-non-hodgkin-lymphoma/

[E_L]

"Epkinly plus R-CHOP is being tested in an ongoing Phase 3 trial in the first-line setting. Allam Fakhoury, AbbVie’s therapeutic area lead in hematology oncology, told Endpoints News that the Phase 3 study in DLBCL is fully enrolled, and the company is “evaluating when the readout will be.” "

[Bulder]

Nice, soon hopefully

[E_L]

Epcoritamab + R-CHOP overcomes high total metabolic tumor volume in high-risk large B-cell lymphoma https://www.youtube.com/watch?v=bTNyW_82_Ks

[E_L]

0:15 / 1:07

Evaluating whether prior bendamustine exposure impacts the efficacy of epcoritamab in DLBCL https://www.youtube.com/watch?v=MFJdK1oXTns

[E_L]

@calliecoombsmd
Much lower severity CRS when using optimized schedule of epcoritamab and with promising response data - high rates of CR and uMRD! Median PFS 12.8 months. https://x.com/calliecoombsmd/status/1866254711781028086

[E_L]

and https://x.com/DrRaulCordoba/status/1866254668105707835

[E_L]

@OncLive
·
10 u
Epcoritamab monotherapy in patients aged >75 with DLBCL who were anthracycline ineligible resulted in ORR 69% (CR 62%) with durable responses. https://x.com/OncLive/status/1866261702074941460 https://x.com/Fer_martinmoro/status/1866262621726576992

[E_L]

a bit of a repeat - City of Hope Reports Novel Immunotherapy in Clinical Trial Shows Promise for Patients With Relapsed or Difficult to Treat Chronic Lymphocytic Leukemia (CLL) - https://www.businesswire.com/news/home/20241208552895/en/City-of-Hope-Reports-Novel-Immunotherapy-in-Clinical-Trial-Shows-Promise-for-Patients-With-Relapsed-or-Difficult-to-Treat-Chronic-Lymphocytic-Leukemia-CLL

[ProinvestorNEWS]

Genmab leverer igen lovende data fra kræfthåb https://proinvestor.com/investornyt/1251772/genmab-leverer-igen-lovende-data-fra-kraefthab

[lahn1]

Tak til EL for alle nyhederne. Noget har ændret sig i aktien, gode nyheder uden fald !

[KWC]

Lidt nyt fra konkurrenterne...

[KWC]

https://www.biospace.com/drug-development/gsk-touts-42-survival-benefit-for-blenrep-in-multiple-myeloma-strengthening-bid-for-market-return?_gl=1*10oq5ns*_up*MQ.._gaMzc1NzEzMDI4LjE3MzM4NDI3NDA._ga_Q90M6MWJZ4MTczMzg0MjczOC4xLjAuMTczMzg0MjczOC4wLjAuMA..